Clinical trial • Respiratory
pembrolizumab for Metastatic non-squamous non-small cell lung cancer|Non-small cell lung cancer
Clinical trial of pembrolizumab for Metastatic non-squamous non-small cell lung cancer|Non-small cell lung cancer. 1666 participants.
Overview
- Trial Therapeutic Area
- Respiratory
- Trial Disease
- Metastatic non-squamous non-small cell lung cancer|Non-small cell lung cancer
- Drug Modality
- Monoclonal antibody
Key dates
- Initial CTIS Submission Date
- 19-01-2024
- First CTIS Authorization Date
- 12-03-2024
Trial design
Clinical trial in France, Spain, Belgium.
- Target Sample Size
- 1666
Recruitment
- Planned Sample Size
- 1666
- Recruitment Window Months
- 72
Geography
- Total Number Of Participants
- 1666
France
- Earliest CTIS Part Ii Submission Date
- 06-02-2024
- Latest Decision Or Authorization Date
- 12-03-2024
- Processing Time Days
- 35
- Number Of Participants
- 1166
Spain
- Earliest CTIS Part Ii Submission Date
- 01-11-2024
- Latest Decision Or Authorization Date
- 23-12-2024
- Processing Time Days
- 52
- Number Of Participants
- 300
Belgium
- Earliest CTIS Part Ii Submission Date
- 04-02-2025
- Latest Decision Or Authorization Date
- 06-03-2025
- Processing Time Days
- 30
- Number Of Participants
- 200
Sponsor
Primary sponsor
- Full Name
- Institut Gustave Roussy
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- Pembrolizumab
- Active Substance
- pembrolizumab
- Modality
- Monoclonal antibody
Related trials
Other published trials that may interest you.
- phospholipid fraction, bovine lung for Idiopathic pulmonary fibrosis
- Allogeneic bone marrow-derived mesenchymal adult stromal cells, ex-vivo expanded for Chronic lung allograft dysfunction (CLAD) | Bronchiolitis obliterans syndrome (BOS) in lung transplant recipients
- IVX-121; HUMAN METAPNEUMOVIRUS, VIRUS-LIKE PROTEIN for Respiratory syncytial virus infection | Human metapneumovirus infection
- Lyophilized bacterial lysates of: Haemophilus influenzae, Streptococcus (Diplococcus) pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Moraxella (Branhamella/Neisseria) catarrhalis (OM-85) for Respiratory tract infections with wheezing lower respiratory illness
- Roginolisib for Advanced non-squamous non-small cell lung cancer